BMJ Open (Apr 2023)

Multidrug chemotherapy, whole-brain radiation and cytarabine therapy for primary central nervous system lymphoma in elderly patients with dose modification based on geriatric assessment: study protocol for a phase II, multicentre, non-randomised study

  • Kenji Yoshida,
  • Tomoyuki Akita,
  • Kosuke Katayama,
  • Kiyohide Kakuta,
  • Takafumi Nishizaki,
  • Fumiyuki Yamasaki,
  • Hirotaka Fudaba,
  • Kenichiro Asano,
  • Takashi Sasayama,
  • Manabu Natsumeda,
  • Taichi Shimabukuro,
  • Kotaro Taguchi,
  • Shinichiro Koizumi,
  • Noriyuki Nakayama,
  • Kentaro Fujii,
  • Ikuno Nishibuchi,
  • Kazuhiko Sugiyama,
  • Ushio Yonezawa,
  • Momii Yasutomo,
  • Yukari Kawasaki,
  • Kazuhiro Tanaka,
  • Hiroaki Nagashima,
  • Yoshihiro Tsukamoto,
  • Makoto Ideguchi,
  • Kazuhiko Kurozumi,
  • Tomohiro Hosoya,
  • Atsushi Kambe

DOI
https://doi.org/10.1136/bmjopen-2022-071350
Journal volume & issue
Vol. 13, no. 4

Abstract

Read online

Introduction Multidrug chemoimmunotherapy with rituximab, high-dose methotrexate, procarbazine and vincristine (R-MPV) is a standard therapy for younger patients with primary central nervous system lymphoma (PCNSL); however, prospective data regarding its use in elderly patients are lacking. This multi-institutional, non-randomised, phase II trial will assess the efficacy and safety of R-MPV and high-dose cytarabine (HD-AraC) for geriatric patients with newly diagnosed PCNSL.Methods and analysis Forty-five elderly patients will be included. If R-MPV does not achieve complete response, the patients will undergo reduced-dose, whole-brain radiotherapy comprising 23.4 Gy/13 fractions, followed by local boost radiotherapy comprising 21.6 Gy/12 fractions. After achieving complete response using R-MPV with or without radiotherapy, the patients will undergo two courses of HD-AraC. All patients will undergo baseline geriatric 8 (G8) assessment before HD-AraC and after three, five and seven R-MPV courses. Patients with screening scores of ≥14 points that decrease to <14 points during subsequent treatment, or those with screening scores <14 points that decrease from the baseline during subsequent treatment are considered unfit for R-MPV/HD-AraC. The primary endpoint is overall survival, and the secondary endpoints are progression-free survival, treatment failure-free survival and frequency of adverse events. The results will guide a later phase III trial and provide information about the utility of a geriatric assessment for defining chemotherapy ineligibility.Ethics and dissemination This study complies with the latest Declaration of Helsinki. Written informed consent will be obtained. All participants can quit the study without penalty or impact on treatment. The protocol for the study, statistical analysis plan and informed consent form have been approved by the Certified Review Board at Hiroshima University (CRB6180006) (approval number: CRB2018-0011). The study is ongoing within nine tertiary and two secondary hospitals in Japan. The findings of this trial will be disseminated through national and international presentations and peer-reviewed publications.Trial registration jRCTs061180093.